AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LISATA THERAPEUTICS, INC. Director's Dealing 2019

Jan 16, 2019

34931_dirs_2019-01-16_813d9f1b-c39e-428a-a41c-6a927d5d06f1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2019-01-14

Reporting Person: MYERS STEVEN S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-14	Restricted Stock Units	A	12121	$4.95	Acquired	57027	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8434	Indirect
Common Stock	1954	Indirect
Common Stock	802	Indirect

Footnotes

F1: Represents 12,121 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 14, 2020.

F2: Includes 12,121 unvested restricted stock units.